SCN5A
ENSG00000183873
Target class
Ion channel
Chromosome
3
Approved drugs
56
Clinical candidates (approved and in development)
64
- Approved drugs
- 56
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 64
- Chemical probe available
- No
- Target name
- SCN5A
- Gene name
- Sodium voltage-gated channel alpha subunit 5
- Gene symbol
- SCN5A
- Previous gene symbols
- CMD1E
- Protein name
- Sodium channel protein type 5 subunit alpha (Sodium channel protein cardiac muscle subunit alpha) (Sodium channel protein type V subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.5) (hH1)
- Nav1.5
- LQT3
- HB1
- HBBD
- PFHB1
- IVF
- HB2
- HH1
- SSS1
- CDCD2
- CMPD2
- ICCD
- Gene biotype
- Protein coding
- Gene family
- Sodium voltage-gated channel alpha subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 8
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 36.13
- Tissue specificity (Gini)
- 0.833
- Tissue specificity (tau)
- 0.965
- KEGG gene identifiers
- hsa:6331
- Protein interaction confidence
- 0.858519
- Protein interaction partners
- 77
- R-HSA-445095
- R-HSA-5576892
- End position
- 38649743
- Start position
- 38548057
- Chromosome
- 3
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Cytoplasm, perinuclear region . Cell membrane, sarcolemma, T-tubule . Cell junction . Note=RANGRF promotes trafficking to the cell membrane. Colocalizes with PKP2 at intercalated disks in the heart (By similarity). .
- Nucleoli
- Nucleoplasm
- Plasma membrane
- PubMed 1309946
- PubMed 19074138
- PubMed 21447824
- PubMed 23085483
- PubMed 23420830
- PubMed 25370050
- PubMed 26279430
- Tissue specificity (tau)
- 0.964546
- Expression inequality (Gini)
- 0.833109
Expression in transcripts per million
- Heart - Atrial Appendage
- 36.13
- Heart - Left Ventricle
- 35.11
- Cervix - Ectocervix
- 5.35
- Cervix - Endocervix
- 4.12
- Nerve - Tibial
- 2.92
Expression in transcripts per million
- Heart - Atrial Appendage36.13
- Heart - Left Ventricle35.11
- Cervix - Ectocervix5.35
- Cervix - Endocervix4.12
- Nerve - Tibial2.92
- Artery - Aorta1.86
- Vagina1.83
- Ovary1.53
- Prostate0.99
- Uterus0.87
- Bladder0.86
- Artery - Tibial0.81
- Colon - Sigmoid0.76
- Brain - Hypothalamus0.76
- Testis0.74
- Brain - Cortex0.64
- Brain - Frontal Cortex (BA9)0.5
- Muscle - Skeletal0.47
- Breast - Mammary Tissue0.46
- Pituitary0.46
- Artery - Coronary0.45
- Fallopian Tube0.43
- Thyroid0.4
- Esophagus - Muscularis0.38
- Colon - Transverse0.37
And 29 more, listed on the interactive page.
- GO:0002027
- GO:0006814
- GO:0010765
- GO:0035725
- GO:0051899
- GO:0060048
- GO:0060307
- GO:0060371
- GO:0060372
- GO:0060373
- GO:0071277
- GO:0086002
- GO:0086004
- GO:0086005
- GO:0086010
- GO:0086012
- GO:0086014
- GO:0086015
- GO:0086016
- GO:0086043
- GO:0086045
- GO:0086046
- GO:0086047
- GO:0086048
- GO:0086067
And 3 more, listed on the interactive page.
- GO:0001518
- GO:0005783
- GO:0005886
- GO:0005901
- GO:0009986
- GO:0014704
- GO:0016020
- GO:0016328
- GO:0030018
- GO:0030315
- GO:0042383
- GO:0005248
- GO:0005515
- GO:0005516
- GO:0017134
- GO:0019899
- GO:0019901
- GO:0019904
- GO:0030506
- GO:0031625
- GO:0044325
- GO:0050998
- GO:0086006
- GO:0086060
- GO:0086061
- GO:0086062
- GO:0086063
- GO:0097110
TdP
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: TdP
Biological samples
- cardiovascular system
Evidence sourcepolymorphic ventricular tachycardia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: polymorphic ventricular tachycardia
Biological samples
- cardiovascular system
Evidence sourcearrhythmias
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: arrhythmias
Biological samples
- cardiovascular system
Evidence sourcelong QT
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: long QT
Biological samples
- cardiovascular system
Evidence source
prolonged QRS interval of ECG
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: prolonged QRS interval of ECG
Biological samples
- cardiovascular system
PubMed 23197038slowed cardiac conduction
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: slowed cardiac conduction
Biological samples
- cardiovascular system
PubMed 23197038
Related records
Trials (4,295)
- : Pulpal Blood Flow With the Use of Intra-nasal Anesthetic
- "Comparison of Intra-articular of 0.2% Ropivacaine vs. 0.75% Ropivacaine in Postoperative of Knee Arthroscopy"
- "Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome"
- "Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."
- "Lignocaine vs GTN Ointment for Postoperative Pain After Hemorrhoidectomy")
- [64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy
- ยง Procaine Periarticular Injections for Pain Reduction in Elderly With Osteoarthritis
- 1% Chloroprocaine(PF) vs. Bupivacaine Spinals
- 1% Lidocaine Paracervical Block for Endometrial Biopsy
- 1% vs. 2 % Lignocaine for Endobronchial Ultrasound Guided Transbronchial Needle Aspiration
- 1% vs. 2 % Lignocaine for Flexible Bronchoscopy
- 10% Lidocaine Spray for Intrauterine Device Insertion
- 16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression
- 2.5% Lidocaine/2.5% Prilocaine Cream for IUD Insertion and Endometrial Biopsy
- 2% Lidocaine Gel in Reducing Postoperative Pain Following Haemorrhoidectomy
- 2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula
- 2%-Mepivacaine With Two Different Vasoconstrictors Solutions in Third Molar Surgery a Comparative Study
- 3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty
- 4% Articaine and 2% Lidocaine by Intraligamentary Technique in Irreversible Pulpitis
- 4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions
Drugs (92)
- Articaine Sodium channel alpha subunit blocker
- Articaine hydrochloride Sodium channel alpha subunit blocker
- AZD1305 Sodium channel protein type V alpha subunit blocker
- AZD7009 Sodium channel protein type V alpha subunit blocker
- Benoxinate Sodium channel alpha subunit blocker
- Benoxinate hydrochloride Sodium channel alpha subunit blocker
- Carbamazepine Sodium channel alpha subunit blocker
- Cenobamate Sodium channel alpha subunit inhibitor
- Chloroprocaine Sodium channel alpha subunit blocker
- Chloroprocaine hydrochloride Sodium channel alpha subunit blocker
- Cocaine Sodium channel alpha subunit blocker
- Cocaine hydrochloride Sodium channel alpha subunit blocker
- Dibucaine Sodium channel protein type V alpha subunit blocker
- Dibucaine hydrochloride Sodium channel protein type V alpha subunit blocker
- Disopyramide Sodium channel alpha subunit blocker
- Disopyramide phosphate Sodium channel alpha subunit blocker
- Dronedarone Sodium channel alpha subunit blocker
- Dronedarone hydrochloride Sodium channel alpha subunit blocker
- Dyclonine Sodium channel alpha subunit blocker
- Dyclonine hydrochloride Sodium channel alpha subunit blocker